Verifi prenatal test: Pivotal trial data

Top-line data from the prospective, blinded, U.S. MELISSA validation trial in 532 maternal blood samples showed that Verinata's verifi prenatal test had 100% sensitivity and 100% specificity for detecting fetal trisomy 21 Down syndrome; 97.3% sensitivity and 100% specificity for detecting fetal trisomy 18 Edwards syndrome; 78.6% sensitivity and 100% specificity for detecting fetal trisomy 13 Patau syndrome; and 93.8% sensitivity and 99.8% specificity for detecting monosomy X Turner syndrome. The test also detected other chromosomal abnormalities including mosaicism for trisomy 21, trisomy 18 and monosomy X, translocation trisomies, a single instance each of trisomy 20 and trisomy 16, and several sex chromosome aneuploidies. ...